Isis Pharmaceuticals Inc. (NASDAQ:ISIP) of Carlsbad, Calif., hasbeen issued two new U.S. patents for novel chemicalintermediates useful in the production of oligonucleotide drugs.The patents cover process chemistries that are aimed atincreasing the capacity and lowering the cost of manufacturingoligonucleotides. One patent addresses a chemical intermediatefor use with solution-phase synthesis of oligos, while the othercovers certain chemical intermediates useful for either solid-phase or solution-phase synthesis of oligos, including chiralcompounds.

(c) 1997 American Health Consultants. All rights reserved.

No Comments